Beth Israel Deaconess Medical Center, Inc.

Beth Israel Deaconess Medical Center, Inc., doing business as BIDMC, is a Harvard Medical School–affiliated non-profit academic medical center in Boston, Massachusetts, that operates as a prime recipient of federal research grants and a subcontractor on research programs, with no federal contract prime awardee activity in the source data. BIDMC competes on an unrestricted, full-and-open basis across the federal funding landscape—the organization holds no SBA set-aside designations.

BIDMC's federal footprint is dominated by biomedical research grants, particularly from the National Institutes of Health. The organization delivers concrete research services spanning basic science laboratory work, translational disease models, advanced proteomics and genomics analysis, clinical trial enrollment and management, and investigator-led fundamental research in oncology, cardiovascular disease, infectious disease, metabolic disease, aging-related conditions, and neuroscience. Recent representative work includes a $1.296 million NIAID grant to develop a trivalent adjuvanted tuberculosis vaccine combining three antigens with superior murine protection and robust human immune responses (CFDA 93.855, awarded August 2026); a $3.481 million NIA grant investigating how excessive amyloid-beta impairs brain lymphatic function in Alzheimer's disease and Down syndrome through molecular, cellular, and functional analysis in mouse models and validation of PIEZO1 pathway activation as a therapeutic strategy (CFDA 93.866, awarded August 2026); and a $2.961 million NIMH grant developing standardized digital health data formats for mental health research through multi-stakeholder consortium governance, iterative standard development, decentralized clinical validation, and adoption pathway integration (CFDA 93.242, awarded August 2026). BIDMC also holds a single-award indefinite-delivery contract with Veterans Integrated Service Network 1 (ceiling $259,360, through July 2027) for integrated walking and tai chi intervention services for veteran populations, with four delivery orders issued since July 2023.

The top five funding agencies by award count account for 56% of recent awards and cover primarily NIH institutes and centers: the National Institutes of Health (479 awards, $100 thousand combined potential value), NHLBI (192 awards, $357 thousand), NIDDK (157 awards), NCI (144 awards, $85 thousand), and NIA (113 awards). By combined potential value, the ranking shifts: NIAID leads with 95 awards worth $21.8 million, followed by NASA Shared Services Center (19 awards, $6.9 million), NHLBI, NIMH, and NIH general. Activity has grown from 121 awards in 2023 to 175 in 2024, then moderated to 157 in 2025 and 117 in 2026. The organization faces a recompete cliff of 158 awards (combined potential value $838 thousand) completing within the next twenty-four months.

BIDMC operates as a prime recipient on 77% of awards (1,499 total) and as a subcontractor on 23% (447 total). In its prime role, BIDMC functions primarily as a recipient of NIH research grants rather than as a federal contractor; in its sub role, BIDMC performs specialized research services for larger academic and research institution primes, including high-content spatial profiling (proteomics, transcriptomics, and multiplexed imaging assays), biomarker discovery, clinical data adjudication, subject recruitment and retention, and translational disease modeling. Named prime recipients BIDMC subcontracts to include Seattle Children's Hospital, Northeastern University, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and the Broad Institute, among others, across NIH and other federal grantor programs. BIDMC's parent is Beth Israel Lahey Health, Inc., a tax-exempt hospital and health-services organization. The organization is a child entity within the Lahey Health system and operates as a prime recipient of substantial federal research funding but does not serve as a prime contractor for federal procurement of goods or services beyond the research grant and Indefinite Delivery Contract contexts.